Pelletized pharmaceutical composition
Patent 5800836 Issued on September 1, 1998. Estimated Expiration Date: 
September 1, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 1, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesCoating compositions for solid medicines New oral form of medicament and a method for producing it Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof Long-acting diclofenac sodium preparation Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat Patent #: 5084287 InventorsAssigneeApplicationNo. 398744 filed on 02/06/1995US Classes:424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)424/480, Cellulose or derivative424/494, Cellulose derivatives424/495, Ethyl cellulose424/497Containing solid synthetic polymersExaminersPrimary: Page, Thurman K.Assistant: Benston, William E. Jr. Attorney, Agent or FirmForeign Patent References
International ClassA61K 009/14Foreign Application Priority Data1992-08-05 AUAbstractA pelletized sustained release pharmaceutical composition including a core element including approximately 0.1 to 95% by weight, based on the total weight of the core element, of an active ingredient of low aqueous solubility; approximately 0.1 to 55% by weight of a core seed; and a core coating for the core element, including approximately 30 to 97% by weight, based on the total weight of the core coating, excluding filler, of an enteric polymer; approximately 3 to 50% by weight of an insoluble polymer; and 0 to approximately 50% by weight of plasticizer, the enteric polymer comprising at least approximately 70% by weight of the total weight of the enteric polymer and insoluble polymer; the core coating being such that the active ingredient is released in a controlled fashion over an extended period in the intestine but substantially no release occurs in the acid environment of the stomach and blood levels of active ingredient are maintained within the therapeutic range over an extended period of time. | |
